HIGHLIGHTS
- who: Zhen-Hua Wu and collaborators from the Taizhou, Zhejiang, China have published the article: Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint, in the Journal: (JOURNAL)
- what: The authors report the discovery and development of a novel anti- SIRPα antibody, BR105, as an approach to deliver the therapeutic benefit of SIRPα-CD47 blockade. The studies demonstrate that BR105 synergizes with other therapeutic antibodies to promote phagocytosis of tumor cells and inhibits tumor growth in a xenograft tumor model.
SUMMARY
Although BR105 binds to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.